Open AccessDetection of Mutations Associated with Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Isolates from Samara Region, Russian Federation
Author(s) -
Vladyslav Nikolayevsky,
Timothy J. Brown,
Yanina Balabanova,
Michael C. Ruddy,
Ivan Fedorin,
Francis Drobniewski
Publication year - 2004
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.42.10.4498-4502.2004
Subject(s) - rpob , inha , isoniazid , mycobacterium tuberculosis , biology , tuberculosis , virology , drug resistance , rifampicin , microbiology and biotechnology , population , genotype , genetics , gene , antibiotics , medicine , environmental health , pathology
High incidence rates of isoniazid-, rifampin-, and multiple-drug-resistant tuberculosis have been reported in countries of the former Soviet Union (FSU). Genotypic (unlike phenotypic) drug resistance assays do not require viable cultures but require accurate knowledge of both the target gene and the mutations associated with resistance. For these assays to be clinically useful, they must be able to detect the range of mutations seen in isolates from the population of tuberculosis patients to which they are applied. Two novel macroarrays were applied to detect mutations associated with rifampin (rpoB ) and isoniazid (katG andinhA ) resistance. In a sample of 233 isolates from patients in Samara, central Russia, 46.5% of isolates possessed mutations in both therpoB and thekatG (orinhA ) genes. Combined results from the macroarrays demonstrated concordance in 95.4 and 90.4% of phenotypically defined rifampin- and isoniazid-resistant isolates, respectively. The contribution of different mutations to resistance was comparable to that reported previously for non-FSU countries, with 90% of rifampin-resistant isolates and 93% of isoniazid resistant isolates due torpoB531 andkatG315 mutations, respectively. The percentage of phenotypically resistant rifampin isolates with no mutations in therpoB codons 509 to 536 was 4.2%, which was similar to previous reports. Novel macroarrays offer a rapid, accurate, and relatively cheap system for the identification of rifampin-, isoniazid-, and multiple-drug-resistantMycobacterium tuberculosis isolates.